Creating medicine is a complex and expensive business. While U.S. biopharmaceutical companies lead the world in drug development, international trade practices can stem the flow of innovation to new markets, depriving patients in need. Limited market penetration also means fewer resources to re-invest in the most successful engine for life-saving advancements on […]